Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27044 | 1.00 | FFAR3 (0.35) | FFAR3SOAT1HCAR2GRIK1GRIK2 | |
| SCHEMBL3555075 | 1.00 | FFAR3 (0.35) | FFAR3SOAT1HCAR2GRIK1GRIK2 | |
| SCHEMBL984690 | 0.86 | FFAR3 (0.32) | FFAR3SOAT1HCAR2 | |
| SCHEMBL12801028 | 0.84 | HCAR2 (0.31) | HCAR2GRIK1GRIK2 | |
| SCHEMBL30965305 | 0.82 | HCAR2 (0.46) | SOAT1HCAR2ALDH1A1 | |
| SCHEMBL31058784 | 0.82 | HCAR2 (0.46) | SOAT1HCAR2ALDH1A1 | |
| Benzophenone SCHEMBL10712584 | 0.82 | ELANE (0.47) | ALDH1A1 | |
| SCHEMBL28845613 | 0.82 | TSHR (0.46) | FFAR3HCAR2ALDH1A1KDM4ETSHR | |
| SCHEMBL6308241 | 0.82 | HDAC3 (0.39) | FFAR3HCAR2GRIK1GRIK2ALDH1A1 | |
| SCHEMBL18044751 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757133-B1 | UV-CURABLE INK FOR DIRECT PLATE MAKING BY INK-JET PRINTING WITH PREPARATION METHOD AND APPLICATION THEREFOR | INST CHEMISTRY CAS (CN) | 2016-12-28 | — | — | EP | claimed |
| EP-2807026-A1 | MULTILAYER SYSTEMS | LANXESS Deutschland GmbH (DE) | 2014-12-03 | — | — | EP | claimed |
| WO-2013110610-A1 | MULTILAYER SYSTEMS | LANXESS DEUTSCHLAND GMBH (DE) | 2013-08-01 | — | — | WO | claimed |
| EP-2620277-A1 | Multi-layer systems | LANXESS Deutschland GmbH (DE) | 2013-07-31 | — | — | EP | claimed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-12227507-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-114555604-B | Pharmaceutical compounds | 辉瑞公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220324873-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-10-13 | — | — | US | disclosed |
| US-20060079707-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| WO-2004052313-A2 | ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| EP-1383733-A2 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030060624-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002085843-A2 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6395920-B1 | OBTAINING 2-SUBSTITUTED AND 2,2- DISUBSTITUTED ACETALS OF MALONDIALDEHYDE FROM ORTHO FORMATES AND SUBSTITUTED VINYL ETHERS IN THE PRESENCE OF AN ACIDIC CATALYST | CREANOVA, INC. | 2002-05-28 | — | — | US | disclosed |
| US-20020040166-A1 | PROCESS FOR PREPARING SUBSTITUTED ACETALS OF MALONDIALDEHYDE | CREANOVA, INC. | 2002-04-04 | — | — | US | disclosed |
| US-5177116-A | Polysiloxane | BASF CORPORATION (US) | 1993-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | FFAR3 2823/4885SOAT1 2303/4885HCAR2 2165/4885 |
| US-12227507-B2 | Pharmaceutical compounds | CHRNA6, GABRA6, CHRNA7 | FFAR3 684/4885SOAT1 1440/4885HCAR2 378/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | FFAR3 2823/4885SOAT1 2303/4885HCAR2 2165/4885 |
| US-20060079707-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | CYP1B1, AZI2, CYP1A1 | FFAR3 3018/4885SOAT1 3837/4885HCAR2 2099/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | FFAR3 2823/4885SOAT1 2303/4885HCAR2 2165/4885 |
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | FFAR3 953/4885SOAT1 1663/4885HCAR2 422/4885 |
| US-20020040166-A1 | PROCESS FOR PREPARING SUBSTITUTED ACETALS OF MALONDIALDEHYDE | AOX1, GPX4, NOX4 | FFAR3 1717/4885SOAT1 1178/4885HCAR2 3037/4885 |
| US-20030060624-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds | INTS6, CYP1B1, CYP1A2 | FFAR3 3924/4885SOAT1 2915/4885HCAR2 2447/4885 |
| US-20220324873-A1 | PHARMACEUTICAL COMPOUNDS | GABRA6, CNR1, CHRNA6 | FFAR3 903/4885SOAT1 1896/4885HCAR2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.